Overview of Activa Parkinson's Control Therapy

Activa Parkinson's Control Therapy was approved in Canada, Europe and Australia in 1998, and in the United States in 2002.

The neurostimulator delivers controlled electrical stimulation to bilaterally implanted electrodes to targeted cells in the subthalamic nucleus (STN) or internal globus pallidus (GPi). The stimulation can control rigidity, bradykinesia/akinesia and/or tremor, while reducing the duration of dyskinesia related to antiparkinsonian medication.^1,2,3 The stimulation can be adjusted via telemetry to meet each patient's needs.

Activa Parkinson's Control Therapy

A surgically implanted Kinetra® dual-channel neurostimulator, similar to a cardiac pacemaker, delivers electrical stimulation to precisely targeted areas on each side of the brain. Bilateral stimulation of these areas controls the signals that cause the disabling bilateral motor symptoms of Parkinson's disease. Patients may also have two Soletra® or Itrel™ II neurostimulators, each of which controls the electrical signals to a single lead.

References

1. Data on file at Medtronic, Inc.
2. Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 1998;339:1105-11.
3. The Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med. 2001;345:956-63.
   

©Medtronic, Inc. 2008                                                   • Contact Medtronic • Privacy Statement • Terms of Use • Site Map